LUMO News and Press, Lumos Pharma Inc. From 08/09/22

The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Lumos Pharma, Inc. 2022 Q2 - Results - Earnings Call Presentation

Lumos Pharma press release ( NASDAQ: LUMO ): Q2 GAAP EPS of -$0.94 beats by $0.04 . Revenue of $0.4M (+3900.0% Y/Y) beats by $0.38M . For further details see: Lumos Pharma GAAP EPS of -$0.94 beats by $0.04, revenue of $0.4M beats by $0.38M

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Patients Anticipated from OraGrowtH212 Trial -- -- Cash Runway into Second ...

Lumos Pharma ( NASDAQ: LUMO ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close. The consensus EPS Estimate is -$0.99 and the consensus Revenue Estimate is $0.02M (+100.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 u...

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. The company will host a conference call ...

The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Lumos Pharma, Inc. 2022 Q1 - Results - Earnings Call Presentation

Lumos Pharma, Inc. (LUMO) Q1 2022 Earnings Conference Call May 10, 2022, 16:30 ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Lori Lawley - CFO & Princ...

Lumos Pharma press release (NASDAQ:LUMO): Q1 GAAP EPS of -$0.92 misses by $0.02. Revenue of $0.11M. Cash and equivalents totaling $86.8 million compared to $94.8 million on December 31, 2021. The Company expects an average cash use of approximately $8.5 to $9.5 million per quarter through 202...

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold-- --Clinical Collaboration In...

AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Mass...